120 related articles for article (PubMed ID: 1449967)
1. Non-invasive MRS in new anticancer drug development.
Workman P; Maxwell RJ; Griffiths JR
NMR Biomed; 1992; 5(5):270-2. PubMed ID: 1449967
[TBL] [Abstract][Full Text] [Related]
2. Demonstration of tumor-selective retention of fluorinated nitroimidazole probes by 19F magnetic resonance spectroscopy in vivo.
Maxwell RJ; Workman P; Griffiths JR
Int J Radiat Oncol Biol Phys; 1989 Apr; 16(4):925-9. PubMed ID: 2703398
[TBL] [Abstract][Full Text] [Related]
3. Preclinical evaluation of the fluorinated 2-nitroimidazole N-(2-hydroxy-3,3,3-trifluoropropyl)-2-(2-nitro-1-imidazolyl) acetamide (SR-4554) as a probe for the measurement of tumor hypoxia.
Aboagye EO; Maxwell RJ; Kelson AB; Tracy M; Lewis AD; Graham MA; Horsman MR; Griffiths JR; Workman P
Cancer Res; 1997 Aug; 57(15):3314-8. PubMed ID: 9242466
[TBL] [Abstract][Full Text] [Related]
4. In vivo 19F magnetic resonance spectroscopy and chemical shift imaging of tri-fluoro-nitroimidazole as a potential hypoxia reporter in solid tumors.
Procissi D; Claus F; Burgman P; Koziorowski J; Chapman JD; Thakur SB; Matei C; Ling CC; Koutcher JA
Clin Cancer Res; 2007 Jun; 13(12):3738-47. PubMed ID: 17575240
[TBL] [Abstract][Full Text] [Related]
5. Novel non-invasive probes for measuring tumor-hypoxia by 19F-magnetic resonance spectroscopy (19F-MRS). Studies in the SCCVII/C3H murine model.
Papadopoulou MV; Pouremad R; Bloomer WD; Wyrwicz A
Anticancer Res; 2006; 26(5A):3259-63. PubMed ID: 17094438
[TBL] [Abstract][Full Text] [Related]
6. Preclinical development and current status of the fluorinated 2-nitroimidazole hypoxia probe N-(2-hydroxy-3,3,3-trifluoropropyl)-2-(2-nitro-1-imidazolyl) acetamide (SR 4554, CRC 94/17): a non-invasive diagnostic probe for the measurement of tumor hypoxia by magnetic resonance spectroscopy and imaging, and by positron emission tomography.
Aboagye EO; Kelson AB; Tracy M; Workman P
Anticancer Drug Des; 1998 Sep; 13(6):703-30. PubMed ID: 9755726
[TBL] [Abstract][Full Text] [Related]
7. Dynamic measurements of hexafluoromisonidazole (CCI-103F) retention in mouse tumours by 1H/19F magnetic resonance spectroscopy.
Jin GY; Li SJ; Moulder JE; Raleigh JA
Int J Radiat Biol; 1990 Dec; 58(6):1025-34. PubMed ID: 1978851
[TBL] [Abstract][Full Text] [Related]
8. Novel fluorinated hypoxia-targeted compounds as Non-invasive probes for measuring tumor-hypoxia by 19F-magnetic resonance spectroscopy (19F-MRS).
Papadopoulou MV; Ji M; Bloomer WD
Anticancer Res; 2006; 26(5A):3253-8. PubMed ID: 17094437
[TBL] [Abstract][Full Text] [Related]
9. In-vitro activity and tissue distribution of new fluorinated meso-tetrahydroxyphenylporphyrin photosensitizers.
Songca SP
J Pharm Pharmacol; 2001 Nov; 53(11):1469-75. PubMed ID: 11732749
[TBL] [Abstract][Full Text] [Related]
10. Pharmacokinetics and metabolism of the mixed-function hypoxic cell sensitizer prototype RSU 1069 in mice.
Walton MI; Workman P
Cancer Chemother Pharmacol; 1988; 22(4):275-81. PubMed ID: 3168141
[TBL] [Abstract][Full Text] [Related]
11. Pharmacokinetics and cytotoxicity of RSU-1069 in subcutaneous 9L tumours under oxic and hypoxic conditions.
Wong KH; Koch CJ; Wallen CA; Wheeler KT
Br J Cancer; 1991 Apr; 63(4):484-8. PubMed ID: 2021530
[TBL] [Abstract][Full Text] [Related]
12. Development of lipophilic anticancer agents for the treatment of brain tumors by the esterification of water-soluble chlorambucil.
Genka S; Deutsch J; Shetty UH; Stahle PL; John V; Lieberburg IM; Ali-Osman F; Rapoport SI; Greig NH
Clin Exp Metastasis; 1993 Mar; 11(2):131-40. PubMed ID: 8444006
[TBL] [Abstract][Full Text] [Related]
13. Pre-treatment energy status of primary rat tumours as the best predictor of response to 5-fluorouracil chemotherapy: a magnetic resonance spectroscopy study in vivo.
Lemaire LP; McSheehy PM; Griffiths JR
Cancer Chemother Pharmacol; 1998; 42(3):201-9. PubMed ID: 9685055
[TBL] [Abstract][Full Text] [Related]
14. Characterization of [18F]fluoroetanidazole, a new radiopharmaceutical for detecting tumor hypoxia.
Rasey JS; Hofstrand PD; Chin LK; Tewson TJ
J Nucl Med; 1999 Jun; 40(6):1072-9. PubMed ID: 10452326
[TBL] [Abstract][Full Text] [Related]
15. Pharmacokinetic basis for the comparative antitumour activity and toxicity of chlorambucil, phenylacetic acid mustard and beta, beta-difluorochlorambucil (CB 7103) in mice.
Lee FY; Coe P; Workman P
Cancer Chemother Pharmacol; 1986; 17(1):21-9. PubMed ID: 3698173
[TBL] [Abstract][Full Text] [Related]
16. Validation of the fluorinated 2-nitroimidazole SR-4554 as a noninvasive hypoxia marker detected by magnetic resonance spectroscopy.
Seddon BM; Maxwell RJ; Honess DJ; Grimshaw R; Raynaud F; Tozer GM; Workman P
Clin Cancer Res; 2002 Jul; 8(7):2323-35. PubMed ID: 12114437
[TBL] [Abstract][Full Text] [Related]
17. The relationship between tumour oxygenation determined by oxygen electrode measurements and magnetic resonance spectroscopy of the fluorinated 2-nitroimidazole SR-4554.
Aboagye EO; Maxwell RJ; Horsman MR; Lewis AD; Workman P; Tracy M; Griffiths JR
Br J Cancer; 1998; 77(1):65-70. PubMed ID: 9459147
[TBL] [Abstract][Full Text] [Related]
18. An investigation of the possibility of chemosensitization by clinically achievable concentrations of misonidazole.
Twentyman PR; Workman P
Br J Cancer; 1983 Feb; 47(2):187-94. PubMed ID: 6824566
[TBL] [Abstract][Full Text] [Related]
19. Synthesis of an (iodovinyl)misonidazole derivative for hypoxia imaging.
Biskupiak JE; Grierson JR; Rasey JS; Martin GV; Krohn KA
J Med Chem; 1991 Jul; 34(7):2165-8. PubMed ID: 2066990
[TBL] [Abstract][Full Text] [Related]
20. Monitoring pharmacokinetics of anticancer drugs: non-invasive investigation using magnetic resonance spectroscopy.
Griffiths JR; Glickson JD
Adv Drug Deliv Rev; 2000 Mar; 41(1):75-89. PubMed ID: 10699306
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
